Trailing-twelve-month (TTM) revenue is $7.37 Billion with a year-over-year growth of +8.60%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-10-31 | $1,861,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-22 |
| Q1 FY2026Period ended 2026-01-31 | $1,798,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-03 |
| Q2 FY2026Period ended 2026-04-30 | $1,835,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-01 |
| Q3 FY2026Period ended 2026-07-31 | $1,878,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-01 |
| TTM revenue | $7,372,000,000 |
Current P/S: $40,890,504,960 market capitalization ÷ $7,372,000,000 TTM revenue = 5.55x.
Market capitalization source: FMP quote. Quote observed 2026-09-09T19:59:59.000Z. Latest revenue period ended 2026-07-31.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q3 FY2026 (2026-07-31): $1.88B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-09T19:59:59.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-10-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-10-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-10-31 · USD | FY20212021-10-31 · USD | FY20222022-10-31 · USD | FY20232023-10-31 · USD | FY20242024-10-31 · USD | FY20252025-10-31 · USD |
|---|---|---|---|---|---|---|
| Agilent CrossLab | $1.9B | $2.2B | $1.5B | $1.6B | $1.6B | $2.9B |
| Applied Markets | N/A | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-10-31 · USD | FY20212021-10-31 · USD | FY20222022-10-31 · USD | FY20232023-10-31 · USD | FY20242024-10-31 · USD | FY20252025-10-31 · USD |
|---|---|---|---|---|---|---|
| Americas | $2.0B | $2.4B | $2.7B | $2.7B | $2.6B | $2.8B |
| Asia Pacific | $1.9B | $2.2B | $2.5B | $2.3B |
$7.37B
$7.37 Billion
+8.60%
vs. $6.79B a year ago (TTM)
+3.72%
5 Year compound annual growth rate
1 Year
+8.60%
3 Year
+1.77%
5 Year
+3.72%
10 Year
+5.98%
15 Year
+0.88%
20 Year
+2.70%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $6.95B | +$438.00M | +6.73% |
| 2024 | $6.51B | ($323.00M) | (4.73%) |
| 2023 | $6.83B | ($15.00M) | (0.22%) |
| 2022 | $6.85B | +$529.00M | +8.37% |
| 2021 | $6.32B | +$980.00M | +18.36% |
| 2020 |
TTM Growth
+8.60%
3-Year CAGR
+1.77%
5-Year CAGR
+3.72%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-09T19:59:59.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| $1.3B |
| Diagnostics and Genomics | $1.0B | $1.3B | $1.4B | $1.4B | $1.7B | N/A |
|---|
| Life Sciences and Applied Markets | $2.4B | $2.8B | $4.0B | $3.9B | $3.2B | $2.7B |
|---|
| $2.2B |
| Europe | $1.4B | $1.7B | $1.7B | $1.8B | $1.8B | $1.9B |
|---|
| $5.34B |
| +$176.00M |
| +3.41% |
| 2019 | $5.16B | +$249.00M | +5.07% |
| 2018 | $4.91B | +$442.00M | +9.88% |
| 2017 | $4.47B | +$270.00M | +6.43% |
| 2016 | $4.20B | +$164.00M | +4.06% |
